BCM
BLUE

Bayesian Capital Management’s bluebird bio BLUE Stock Holding History

Bayesian Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,022
Closed -$51.8K – 753
2024
Q1 		$51.8K Buy
+2,022
New +$51.8K ﹤0.01% 735
2023
Q1 		– Sell
-7,030
Closed -$973K – 793
2022
Q4 		$973K Buy
7,030
+1,050
+18% +$148K 0.14% 183
2022
Q3 		$757K Buy
+5,980
New +$677K 0.15% 184
2021
Q1 		– Sell
-826
Closed -$463K – 539
2020
Q4 		$463K Buy
826
+293
+55% +$186K 0.12% 224
2020
Q3 		$373K Buy
+533
New +$416K 0.09% 294
2018
Q1 		– Sell
-291
Closed -$671K – 595
2017
Q4 		$671K Buy
+291
New +$591K 0.14% 253

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bayesian Capital Management's BLUE Position: Q2 2024 in Review

Bayesian Capital Management sold out of bluebird bio (BLUE) in Q2 2024, closing a stake of 2,022 shares — an estimated $51.8K sold.

Bayesian Capital Management first reported a position in BLUE in Q4 2017 and held it in 6 quarters. The position peaked at $973K in Q4 2022. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2024.

  • Bayesian Capital Management reported no remaining bluebird bio position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 2,022 bluebird bio shares in Q2 2024, an estimated $51.8K.
  • Bayesian Capital Management first reported a position in bluebird bio in Q4 2017 and held it in 6 quarters.
  • Bayesian Capital Management's bluebird bio position peaked at $973K in Q4 2022.
  • 150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.